Condition
Central Nervous System Injury
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Completed2
Unknown2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04359914Completed
Neurocognitive Impairment in Patients With COVID-19
NCT04127617Not ApplicableUnknownPrimary
Effects of Osteopathic Manipulative Treatment in People With Neurogenic Bowel Dysfunction
NCT03190252Completed
Inflammatory and Cerebrospinal Biochemical Markers in Blood After Trimix Diving
NCT03291366Phase 1UnknownPrimary
Mesenchymal Stem Cells in Central Nervous System injury2017
Showing all 4 trials